VAR 200 is claimed to eliminate accumulated lipids from the kidney. Credit: Robina Weermeijer on Unsplash.

ZyVersa Therapeutics has received a patent from the European Patent Office for its VAR 200 (2-hydroxypropyl-beta-cyclodextrin) to treat patients with diabetic nephropathy/diabetic kidney disease.

Developed in the laboratories of the University of Miami in the US, VAR 200 is a cholesterol efflux mediator that is claimed to eliminate accumulated lipids from the kidney.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It is currently in its Phase IIa development stage.

This asset is being evaluated to cut down the build-up of renal cholesterol and lipid that harms the filtration system of kidneys in individuals with glomerular diseases such as focal segmental glomerulosclerosis, diabetic kidney disease and Alport syndrome.

ZyVersa received a global licence to develop and market VAR 200 from L&F Research.

See Also:

In June 2023, the European Patent Office issued a notice of intention to grant a patent for VAR 200.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

ZyVersa Therapeutics co-founder, chairman, CEO and president Stephen Glover stated: “Approval of this patent claiming our cholesterol efflux mediator VAR 200 for use in treating diabetic kidney disease speaks to the innovative and important research conducted by Dr Fornoni and her team involving removal of excess cholesterol and lipids that damage the kidneys’ filtration system.

“Strengthening our intellectual property portfolio for VAR 200 and expanding our patent protection and exclusive rights into additional geographic regions will further enable ZyVersa to increase shareholder value as VAR 200 advances into clinical trials, which are planned for initiation in the fourth quarter of this year.”